{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T11:41:23Z","timestamp":1792669283456,"version":"4.5.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:00:00Z","timestamp":1792627200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:00:00Z","timestamp":1792627200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100008021","name":"Bristol-Myers Squibb Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008021","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiol Ther"],"DOI":"10.1007\/s40119-026-00483-3","type":"journal-article","created":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T11:04:03Z","timestamp":1792667043000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-World Effectiveness of Mavacamten in Canada: Insights from the MAVEN Study"],"prefix":"10.1007","author":[{"given":"Michael R.","family":"Ward","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew M.","family":"Crean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Desplantie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin D.","family":"Tyrrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Corriveau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Brellier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin C.","family":"Ong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,22]]},"reference":[{"key":"483_CR1","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.jacc.2014.05.003","volume":"64","author":"BJ Maron","year":"2014","unstructured":"Maron BJ, Ommen SR, Semsarian C, Spirito P, Olivotto I, Maron MS. Hypertrophic cardiomyopathy: present and future, with translation into contemporary cardiovascular medicine. J Am Coll Cardiol. 2014;64:83\u201399.","journal-title":"J Am Coll Cardiol"},{"key":"483_CR2","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.5603\/KP.2014.0212","volume":"72","author":"PM Elliott","year":"2014","unstructured":"Elliott PM, Anastasakis A, Borger MA, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy. Polish Heart J. 2014;72:1054\u2013126.","journal-title":"Polish Heart J"},{"key":"483_CR3","doi-asserted-by":"publisher","first-page":"e212","DOI":"10.1016\/j.jacc.2011.06.011","volume":"58","author":"BJ Gersh","year":"2011","unstructured":"Gersh BJ, Maron BJ, Bonow RO, et al. 2011 ACCF\/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines developed in collaboration with the American Association for Thoracic Surgery, American Society of echocardiography, American Society of nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2011;58:e212\u201360.","journal-title":"J Am Coll Cardiol"},{"key":"483_CR4","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1056\/NEJMra1710575","volume":"379","author":"BJ Maron","year":"2018","unstructured":"Maron BJ. Clinical course and management of hypertrophic cardiomyopathy. N Engl J Med. 2018;379:655\u201368.","journal-title":"N Engl J Med"},{"key":"483_CR5","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1161\/CIRCULATIONAHA.117.033200","volume":"138","author":"CY Ho","year":"2018","unstructured":"Ho CY, Day SM, Ashley EA, et al. Genotype and lifetime burden of disease in hypertrophic cardiomyopathy: insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe). Circulation. 2018;138:1387\u201398.","journal-title":"Circulation"},{"key":"483_CR6","doi-asserted-by":"publisher","unstructured":"Wang A, Garcia-Pavia P, Masri A, et al. Aficamten in obstructive hypertrophic cardiomyopathy: a multi-domain, patient-level analysis of the MAPLE-HCM trial. JACC. 2025;87(8). https:\/\/doi.org\/10.1016\/j.jacc.2025.10.057","DOI":"10.1016\/j.jacc.2025.10.057"},{"key":"483_CR7","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1126\/science.aad3456","volume":"351","author":"EM Green","year":"2016","unstructured":"Green EM, Wakimoto H, Anderson RL, et al. A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice. Science. 2016;351:617\u201321.","journal-title":"Science"},{"key":"483_CR8","doi-asserted-by":"publisher","first-page":"16571","DOI":"10.1074\/jbc.M117.776815","volume":"292","author":"RF Kawas","year":"2017","unstructured":"Kawas RF, Anderson RL, Ingle SRB, Song Y, Sran AS, Rodriguez HM. A small-molecule modulator of cardiac myosin acts on multiple stages of the myosin chemomechanical cycle. J Biol Chem. 2017;292:16571\u20137.","journal-title":"J Biol Chem"},{"key":"483_CR9","doi-asserted-by":"publisher","first-page":"E8143","DOI":"10.1073\/pnas.1809540115","volume":"115","author":"RL Anderson","year":"2018","unstructured":"Anderson RL, Trivedi DV, Sarkar SS, et al. Deciphering the super relaxed state of human \u03b2-cardiac myosin and the mode of action of mavacamten from myosin molecules to muscle fibers. Proc Natl Acad Sci USA. 2018;115:E8143\u201352.","journal-title":"Proc Natl Acad Sci USA"},{"key":"483_CR10","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","volume":"396","author":"I Olivotto","year":"2020","unstructured":"Olivotto I, Oreziak A, Barriales-Villa R, et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2020;396:759\u201369.","journal-title":"Lancet"},{"key":"483_CR11","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1001\/jamacardio.2023.3342","volume":"8","author":"MY Desai","year":"2023","unstructured":"Desai MY, Owens A, Wolski K, et al. Mavacamten in patients with hypertrophic cardiomyopathy referred for septal reduction: week 56 results from the VALOR-HCM randomized clinical trial. JAMA cardiology. 2023;8:968\u201377.","journal-title":"JAMA cardiology"},{"key":"483_CR12","unstructured":"Bristol Myers Squibb Canada. CAMZYOS (mavacamten) product monograph. 2025. https:\/\/www.bms.com\/assets\/bms\/ca\/documents\/productmonograph\/CAMZYOS_EN_PM.pdf. Accessed"},{"key":"483_CR13","unstructured":"US Food and Drug Administration (FDA). CAMZYOS (mavacamten):prescribing information. 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/214998s000lbl.pdf"},{"key":"483_CR14","unstructured":"European Medicines Agency (EMA). CAMZYOS (mavacamten). 2023. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/camzyos-epar-product-information_en.pdf"},{"key":"483_CR15","doi-asserted-by":"publisher","first-page":"A4140424","DOI":"10.1161\/circ.150.suppl_1.4140424","volume":"150","author":"KC Ong","year":"2024","unstructured":"Ong KC, Crean A, Garceau P, et al. Early insights on mavacamten usage in Canada: a retrospective cohort study of the patient support program. Circulation. 2024;150:A4140424\u2013A4140424.","journal-title":"Circulation"},{"key":"483_CR16","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.cjco.2026.02.012","volume":"8","author":"K Ong","year":"2026","unstructured":"Ong K, Garceau P, Crean AM, et al. Early insights on mavacamten usage in Canada: a retrospective cohort study of the mavacamten patient support program. CJC Open. 2026;8:627\u201336.","journal-title":"CJC Open"},{"key":"483_CR17","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.124.012441","volume":"18","author":"MY Desai","year":"2025","unstructured":"Desai MY, Seto D, Cheung M, et al. Mavacamten: real-world experience from 22 months of the Risk Evaluation and Mitigation Strategy (REMS) program. Circ Heart Fail. 2025;18:e012441.","journal-title":"Circ Heart Fail"},{"key":"483_CR18","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1002\/pds.3891","volume":"25","author":"Public Policy Committee ISoP","year":"2016","unstructured":"Public Policy Committee ISoP. Guidelines for good pharmacoepidemiology practice (GPP). Pharmacoepidemiol Drug Saf. 2016;25:2\u201310.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"483_CR19","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1007\/s40265-022-01739-7","volume":"82","author":"SJ Keam","year":"2022","unstructured":"Keam SJ. Mavacamten: first approval. Drugs. 2022;82:1127\u201335.","journal-title":"Drugs"},{"key":"483_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacadv.2026.102956","volume":"5","author":"LW Liang","year":"2026","unstructured":"Liang LW, Takayama H, Nazif TM, Gojcaj L, Shimada YJ, Weiner SD. Real-world experience with mavacamten in SRT-eligible obstructive HCM. JACC Adv. 2026;5:102956.","journal-title":"JACC Adv"},{"key":"483_CR21","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.jacc.2022.04.048","volume":"80","author":"MY Desai","year":"2022","unstructured":"Desai MY, Owens A, Geske JB, et al. Myosin inhibition in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy. J Am Coll Cardiol. 2022;80:95\u2013108.","journal-title":"J Am Coll Cardiol"},{"key":"483_CR22","first-page":"1123","volume":"12","author":"N Reza","year":"2024","unstructured":"Reza N, Dubey A, Carattini T, et al. Real-world experience and 36-week outcomes of patients with symptomatic obstructive hypertrophic cardiomyopathy treated with mavacamten. Heart Fail. 2024;12:1123\u20135.","journal-title":"Heart Fail"},{"key":"483_CR23","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.034069","volume":"13","author":"D Ramonfaur","year":"2024","unstructured":"Ramonfaur D, Gasperetti A, Blake VE, et al. Eighteen\u2010month real\u2010world experience using mavacamten for treatment of obstructive hypertrophic cardiomyopathy in a racially diverse population. J Am Heart Assoc. 2024;13:e034069.","journal-title":"J Am Heart Assoc"},{"key":"483_CR24","doi-asserted-by":"crossref","unstructured":"Becker F, Novotny J, Jansen N, et al. Real-world experience in initiation of treatment with the selective cardiomyosin inhibitor mavacamten in an outpatient clinic cohort during the 12-week titration period. Clin Res Cardiol. 2026;115(5):725\u201331.","DOI":"10.1007\/s00392-024-02544-w"},{"key":"483_CR25","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1002\/ehf2.14882","volume":"12","author":"Z Abood","year":"2025","unstructured":"Abood Z, Jan MF, Ashraf M, et al. Mavacamten in real\u2010life practice: initial experience at a hypertrophic cardiomyopathy centre. ESC Heart Fail. 2025;12:672\u20136.","journal-title":"ESC Heart Fail"},{"key":"483_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2024.1429230","volume":"11","author":"DS Kim","year":"2024","unstructured":"Kim DS, Chu EL, Keamy-Minor EE, et al. One-year real-world experience with mavacamten and its physiologic effects on obstructive hypertrophic cardiomyopathy. Front Cardiovasc Med. 2024;11:1429230.","journal-title":"Front Cardiovasc Med"},{"key":"483_CR27","doi-asserted-by":"publisher","first-page":"5071","DOI":"10.1093\/eurheartj\/ehae579","volume":"45","author":"P Garcia-Pavia","year":"2024","unstructured":"Garcia-Pavia P, Or\u0119ziak A, Masri A, et al. Long-term effect of mavacamten in obstructive hypertrophic cardiomyopathy. Eur Heart J. 2024;45:5071\u201383.","journal-title":"Eur Heart J"},{"key":"483_CR28","doi-asserted-by":"publisher","first-page":"A4139196","DOI":"10.1161\/circ.150.suppl_1.4139196","volume":"150","author":"J Macnamara","year":"2024","unstructured":"Macnamara J, Adler A, Maor E, et al. Long-term effectiveness and safety of mavacamten in a real-world, multi-center, global study: preliminary results of COLLIGO-HCM from a diverse cohort in the United States. Circulation. 2024;150:A4139196\u2013A4139196.","journal-title":"Circulation"},{"key":"483_CR29","first-page":"164","volume":"12","author":"F Rader","year":"2024","unstructured":"Rader F, Or\u0119ziak A, Choudhury L, et al. Mavacamten treatment for symptomatic obstructive hypertrophic cardiomyopathy: interim results from the MAVA-LTE study, EXPLORER-LTE cohort. Heart Failure. 2024;12:164\u201377.","journal-title":"Heart Failure"},{"key":"483_CR30","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.pcad.2024.02.001","volume":"86","author":"MY Desai","year":"2024","unstructured":"Desai MY, Hajj-Ali A, Rutkowski K, et al. Real-world experience with mavacamten in obstructive hypertrophic cardiomyopathy: observations from a tertiary care center. Prog Cardiovasc Dis. 2024;86:62\u20138.","journal-title":"Prog Cardiovasc Dis"}],"container-title":["Cardiology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-026-00483-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40119-026-00483-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-026-00483-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T11:04:05Z","timestamp":1792667045000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40119-026-00483-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,22]]},"references-count":30,"alternative-id":["483"],"URL":"https:\/\/doi.org\/10.1007\/s40119-026-00483-3","relation":{},"ISSN":["2193-8261","2193-6544"],"issn-type":[{"value":"2193-8261","type":"print"},{"value":"2193-6544","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,22]]},"assertion":[{"value":"11 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Stephanie Corriveau and Florence Brellier are employees of Bristol Myers Squibb Company. Michael R. Ward has received consulting and speaking fees from Bristol Myers Squibb Company. Andrew M. Crean has received research support from and serves on the Speakers Bureau for Bristol Myers Squibb Company. Olivier Desplantie, Benjamin D. Tyrrell, and Kevin C. Ong have nothing to disclose.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was reviewed and approved by the relevant Research Ethics Boards\/Institutional Review Boards at each participating site, which granted a waiver of informed consent because the study involved the retrospective use of de-identified patient data. The study was conducted in accordance with the Guidelines for Good Pharmacological Practices (GPP) and applicable regulatory requirements. A waiver of consent was obtained from the research ethics board at each participating site prior to the abstraction and use of routinely collected, pseudo-ananymized, medical rescord data, in accordance with local requirements. All research procedures complied with the\u00a0ethical principles of the Declaration of Helsinki. Ethics approval was provided by the Advarra Institutional Review Board (IRB00000971), the Western University Health Sciences Research Ethics Board (HSREB) (IRB00000940), the Ottawa Health Science Network Research Ethics Board (OHSN-REB) (IRB00002616), the Health Research Ethics Board of Alberta\u2014Community Health Committee (HREBA-CHC) (IRB1240005), and the University of British Colombis Providence Health Care Research Ethics Board (UBC-PHC REB) (IRB00000777).","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}